Autoimmune hemolytic anemia (AIHA) is a well known complication of chronic lymphocytic leukemia (CLL). Steroids are the first line of treatment and there are limited effective treatment options for ...

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for ...

We enrolled 50 patients with MCL in this single-institution, single-arm, phase II clinical trial (NCT01880567). Patients with Ki-67% ≥ 50% and blastoid morphology were excluded. Ibrutinib was ...

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked ...

To address this issue better, the GITMO (Italian Group Bone Marrow Transplant) performed a retrospective study concerning the use of Rituximab in patients with refractory cGHVD. The results of this ...

An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis who had an incomplete response to the standard ursodeoxycholic ...

Please provide your email address to receive an email when new articles are posted on . Patients with pemphigus treated with rituximab had a longer disease-free survival than those treated with ...

Rituximab (Rituxan) may be a useful option for children with chronic steroid-dependent Henoch-Schonlein purpura, a small retrospective review suggested. Among eight children with this chronic ...

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

Incyte Biosciences Japan G.K. (INCY) on Monday reported the approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi (tafasitamab) in combination with rituximab and lenalidomide ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has approved rituximab-arrx, in ...

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Minjuvi ® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with ...